Given that HMGA2 is normally expressed mainly during embryonic/fetal development and aberrantly re-expressed in many human malignancies [26, 52], our integrated study identified an important cancer cell-specific marker for future personalized therapeutic interventions with TOP1 poisons and DNA synthesis inhibitors. The gene discussed is TOP1; the disease is cancer.